Lorundrostat for Patients With Uncontrolled Hypertension: A Systematic Review With Meta-Analysis and Trial Sequential Analysis
Lorundrostat effectively lowered blood pressure but increased dose-dependent risk of hyperkalemia. These findings support its potential as a novel therapy for uncontrolled hypertension, while emphasizing the need for longer-term cardiovascular outcome trials and direct comparisons with mineralocorticoid receptor antagonists concerning efficacy and safety.
Authors
- Luiz Aparecido Bortolotto (ORCID: https://orcid.org/0000-0002-4865-6442)
- Lucca Moreira Lopes (ORCID: https://orcid.org/0000-0002-2770-2198)
- Henrique Alexsander Ferreira Neves (ORCID: https://orcid.org/0000-0003-0988-5282)
- Jamil Cherem Schneider
- Kevlin de Souza
- Webster Donaldy (ORCID: https://orcid.org/0009-0001-2342-5349)
- Vicente Morales Ribeiro
- Hermes Estevam Torega Celkevicius
- Douglas Nunes Cavalcante (ORCID: https://orcid.org/0000-0001-5760-6423)
- Giovanna Cristina Gonçalves Camacho
- Rafael Henkes Machado
Institutions
- Johns Hopkins University (US)
- Universidade de São Paulo (BR)
- Hospital Israelita Albert Einstein (BR)
- Harlem Hospital Center (US)
- Universidade do Sul de Santa Catarina (BR)
- Faculdade Redentor (BR)
- Faculdade da Serra Gaúcha (BR)
- Hospital Socor (BR)
- University of Kansas Medical Center (US)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Universidade Federal do Paraná (BR)
Publication Details
- Journal
- American Journal of Hypertension
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1093/ajh/hpaf246
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00